Illumina SNP Collaboration Will Study Preterm Births
Illumina, which garners most of its small revenue bundle from SNP genotyping services, has signed on Boston University Medical Center as a customer for research into preterm births, the company said last week.
Separately, the company reported that it had lost $8.4 million for the quarter, while revenues inched up to $761,000 from $485,000 for the same period of 2000, and expenses reached $9.7 million, compared to $7.2 million for the same period last year.
The San Diego-based fiber optic bead array company, which claims it can process nearly a million genotypes a day, has also recently announced similar SNP-genotyping deals with Johns Hopkins Medical University Institute of Genetic Medicine and GlaxoSmithKline.
Xeotron Wins $3M DARPA Grant to Build Oligo Assembly Technology
Xeotron, a Houston-based chip startup, has reeled in a $3 million grant from the US Defense Advanced Research Projects Agency to develop a system for multi-strand oligonucleotide synthesis.
Xeotron is aiming to shorten the process of oligo synthesis to under 12 hours, making it possible to synthesize large segments in roughly 24 hours.
The company’s technology is based on in situ synthesis coupled with digital light and photosensitive chemistry in a microfluidic chip.
This DARPA grant, funded in connection with the US Navy’s Office of Special Technology, follows several similar grants awarded recently to Orchid Biosciences and Agilent Technologies for oligo synthesis.
BioProcessors Raises $6M in Financing for Cell Culture Microfluidics
BioProcessors, a company developing microfluidics devices for the growth of cell cultures, has raised $6 million in a Series A financing. The company is planning to develop its devices, which it said allow for increased environmental control of cell growth, for cell-based screening, scientific cell culture research, and ADME-tox screening.
Oxford Biosciences led the financing round, which was joined by Rowland Capital and Sequoia International Investments.